BioCryst制药 BCRX 深 沪
已收盘 01-30 16:00:00 美东时间
6.58
-0.090
-1.35%
华盛通- 最 高6.75
- 今 开6.61
- 成交量 329.48万股
- 最 低 6.42
- 昨 收 6.67
- 总市值 13.88亿
- 52周最高 11.31
- 市盈率 静 --
- 换手率 1.56%
- 52周最低 6.00
- 委 比 -99.64%
- 总股本 2.11亿
- 历史最高 19.99
- 量 比 0.77
- 振 幅 4.95%
- 历史最低 1.08
- 每 手 1
- 风险率 1.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13
RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $14 to $13.
01-30 23:34
财报速睇 | BioCryst制药 2025财年Q3营收0.01亿美元，去年同期无营收；归母净利润亏损0.32亿美元，同比亏损扩大29.0%
华盛资讯1月24日讯，BioCryst制药公布2025财年Q3业绩，公司Q3营收0.01亿美元，去年同期无营收，归母净利润亏损0.32亿美元，同比亏损扩大29.0%。
01-24 10:04
BRIEF-Astria Stockholders Vote To Approve Acquisition By Biocryst
BRIEF-Astria Stockholders Vote To Approve Acquisition By Biocryst Jan 21 (Reuters) - Astria Therapeutics Inc ATXS.O : ASTRIA STOCKHOLDERS VOTE TO APPROVE ACQUISITION BY BIOCRYST Source text: ID:nBw7DYHBTa Further company coverage: ATXS.O (( Reuters.Briefs@thomsonreuters.com ;))
01-22 05:42
BioCryst Pharma Sees FY2026 Sales $635.000M-$660.000M vs $657.200M Est
BioCryst Pharma (NASDAQ:BCRX) sees FY2026 sales of $635.000 million-$660.000 million vs $657.200 million analyst estimate.
01-12 20:26
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
FDA Approves BioCryst's NDA For Use Of Oral Pellet Formulation Of Once-Daily ORLADEYO For Prophylactic Therapy In Pediatric Patients With Hereditary Angioedema Aged 2 To <12 Years
–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration-–Showed early and sustained reductions in
2025-12-12 20:02
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
Needham Maintains Buy on BioCryst Pharma, Lowers Price Target to $18
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $20 to $18.
2025-11-04 18:41
BioCryst Pharma Raises FY2025 Sales Guidance from $580.000M-$600.000M to $590.000M-$600.000M vs $625.558M Est
BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to $590.000 million-$600.000 million vs $625.558 million estimate.
2025-11-03 20:01
